ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1449

Development of a Predictive Score of Successful TNF Inhibitor Tapering in Patients with Rheumatoid Arthritis Remission

Clothilde Barral1, David Hajage2, Bruno Fautrel3, Pierre Lafforgue1, Florence Tubach2 and Thao Pham1, 1Rheumatology, APHM, Aix Marseille Univ, Marseille, France, 2APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 75018 75013, Paris, France, Paris, France, 3Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biologics, remission and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Tapering trials confirmed the feasibility of TNF inhibitors (TNFi) tapering for a relevant proportion of patients in remission and/or low disease activity. However, there are no consensual predictors of a good response to therapeutic spacing among patients with rheumatoid arthritis (RA) in remission. We aimed to develop a predictive score of successful TNFi tapering.

Methods:

Post-hoc analysis of a controlled trial of a tapering strategy in RA patients, fulfilling ACR 1987 criteria, treated with subcutaneous TNFi with sustained remission, randomized to either spacing or maintaining TNFi. We used the data of the Spacing arm.

Performances of several variables (DAS28, SDAI, CDAI, CRP, ACPA status, HAQ, patient/physician global assessment, and booleen remission criteria) were assessed for the prediction of successful TNFi tapering, defined as reaching at least 25% tapering of the full regimen during at least 6 months, using sensitivity (Se) and specificity (Spe) for dichotomous variables, or the area under the ROC curve (AUC) and its 95% confidence interval for continuous variables.

A predictive score of successful tapering was constructed using LASSO regression modeling to avoid overfitting (R software version 3.2.1).

Results:

The main characteristic of the 64 patients of the Spacing arm were the following (mean ± SD): age 54.3 ± 10.7 years, disease duration 8.3 ± 5.4 years, and DAS 28 1.9 ± 0.6.

The baseline variables were similar between patients who failed or succeeded at TNFi spacing, except for the HAQ score (0.30 in the group success and 0.89 in the failure group, p = 0.01) and the CRP (2.35 mg/l versus 3.48 mg/l, respectively, p=0.02).

Baseline variable performance in predicting successful TNFi spacing: None of the tested variables was able to predict successful TNFi spacing, except the HAQ score and the CRP. A HAQ threshold ≥ 1.125 had a Spe of 93% and an AUC: 0.713 (CI95%: 0.540-0.886). A CRP threshold ≥ 6.8 mg/l had a Spe of 0.97 and an AUC: 0.689 (CI95%: 0.547-0.831).

Predicting score: A composite score able to predict successful TNFi spacing has been elaborated, including ACPA status, Boolean criteria, SDAI, CRP and HAQ. A 0.5 threshold predicted successful TNFi spacing with Spe = 100% and Se = 54% (AUC: 0.829; CI95%: 0.671 – 0.986).

Conclusion:

The remission maintenance in rheumatoid arthritis after TNFi spacing is possible. Our results showed that in a population of RA patients in remission with TNFi, baseline HAQ and CRP are independent predictor factors of successful tapering. We have developed a composite index able to predict successful TNFi spacing, with an AUC of 0.829 and a 100% Spe. A validation study will be needed to confirm its ability to select patients for treatment decrease.


Disclosure: C. Barral, None; D. Hajage, None; B. Fautrel, None; P. Lafforgue, None; F. Tubach, None; T. Pham, None.

To cite this abstract in AMA style:

Barral C, Hajage D, Fautrel B, Lafforgue P, Tubach F, Pham T. Development of a Predictive Score of Successful TNF Inhibitor Tapering in Patients with Rheumatoid Arthritis Remission [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/development-of-a-predictive-score-of-successful-tnf-inhibitor-tapering-in-patients-with-rheumatoid-arthritis-remission/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-a-predictive-score-of-successful-tnf-inhibitor-tapering-in-patients-with-rheumatoid-arthritis-remission/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology